Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Receivables - Accured (2023 - 2025)

Prokidney (PROK) has disclosed Receivables - Accured for 3 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables - Accured fell 75.75% to $1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.2 million, a 75.75% decrease, with the full-year FY2024 number at $2.4 million, up 77.96% from a year prior.
  • Receivables - Accured was $1.2 million for Q3 2025 at Prokidney, down from $1.8 million in the prior quarter.
  • In the past five years, Receivables - Accured ranged from a high of $8.1 million in Q2 2023 to a low of $714000.0 in Q3 2023.
  • A 3-year average of $3.0 million and a median of $1.9 million in 2024 define the central range for Receivables - Accured.
  • Peak YoY movement for Receivables - Accured: skyrocketed 614.57% in 2024, then crashed 75.75% in 2025.
  • Prokidney's Receivables - Accured stood at $1.4 million in 2023, then skyrocketed by 77.96% to $2.4 million in 2024, then tumbled by 49.45% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for PROK's Receivables - Accured are $1.2 million (Q3 2025), $1.8 million (Q2 2025), and $1.8 million (Q1 2025).